FindTrial
Sign In

Evaluation of the efficacy of memantine in the treatment of fibromyalgia: a double-blind randomized control clinical trial.

Evaluation of the efficacy of memantine in the treatment of fibromyalgia: a double-blind randomized control clinical trial.

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-006244-73-ES
Enrollment
Unknown
Registered
2012-04-12
Start date
2012-05-29
Completion date
Unknown
Last updated
2012-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Interventions

Trade Name: Ebixa Pharmaceutical Form: Film-coated tablet INN or Proposed INN: MEMANTINE HYDROCHLORIDE CAS Number: 19982-08-2 Concentration unit: mg milligram(s) Concentration type: equal Concentratio

Sponsors

Instituto Aragonés de Ciencias de la Salud
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 60 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: To evaluate the efficacy of memantine in the treatment of pain;Secondary Objective: - To assess the efficacy of memantine in the treatment of anxiety, cognitive status and quality of life in patients with fibromyalgia. - To assess the efficacy of memantine in reducing brain glutamate levels by MRS. - To evaluate the effect of memantine in CNS by EEGq and cordance.;Primary end point(s):—

Countries

Spain

Contacts

Public ContactRaquel Arcega

Instituto Aragonés de Ciencias de la Salud

rarcega.iacs@aragon.es+34976716959

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Mar 24, 2026